Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%

MT Newswires Live

2025/06/05

Mayne Pharma Group's (ASX:MYX) board continues to recommend shareholders accept the scheme implementation deed (SID) to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.

The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.

The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.

Shares of the company rose past 3% in recent Thursday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541166400"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541166400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541166400?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541166400","market":"sg","top_or_hot":-1,"title":"Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%","media":"MT Newswires Live","content":"<html><body><p> Mayne Pharma Group's (ASX:MYX) board continues to recommend shareholders accept the scheme implementation deed (SID) to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.</p><p>The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.</p><p>The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.</p><p>Shares of the company rose past 3% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMayne Pharma Continues to Recommend Shareholders Accept Scheme Implementation Deed With Cosette; Shares Rise 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-05 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mayne Pharma Group's (ASX:MYX) board continues to recommend shareholders accept the scheme implementation deed (SID) to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.</p><p>The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.</p><p>The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.</p><p>Shares of the company rose past 3% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2541166400","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541166400","pubTimestamp":1749088522,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mayne Pharma Group's  board continues to recommend shareholders accept the scheme implementation deed  to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.Shares of the company rose past 3% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","SID":"巴西国家黑色冶金","BK7508":"医药生物股","MYX.AU":"MAYNE PHARMA GROUP LTD","BK4006":"钢铁"},"translate_title":"Mayne Pharma继续建议股东接受与Cosette的计划实施契约；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":0.9,"SID":1},"content_text":"Mayne Pharma Group's (ASX:MYX) board continues to recommend shareholders accept the scheme implementation deed (SID) to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.Shares of the company rose past 3% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}